These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 34228302)

  • 1. Lessons from bariatric surgery: Can increased GLP-1 enhance vascular repair during cardiometabolic-based chronic disease?
    Bakbak E; Terenzi DC; Trac JZ; Teoh H; Quan A; Glazer SA; Rotstein OD; Al-Omran M; Verma S; Hess DA
    Rev Endocr Metab Disord; 2021 Dec; 22(4):1171-1188. PubMed ID: 34228302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoration of blood vessel regeneration in the era of combination SGLT2i and GLP-1RA therapy for diabetes and obesity.
    Terenzi DC; Bakbak E; Teoh H; Krishnaraj A; Puar P; Rotstein OD; Cosentino F; Goldenberg RM; Verma S; Hess DA
    Cardiovasc Res; 2024 Feb; 119(18):2858-2874. PubMed ID: 38367275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GLP-1RA therapy increases circulating vascular regenerative cell content in people living with type 2 diabetes.
    Park B; Krishnaraj A; Teoh H; Bakbak E; Dennis F; Quan A; Hess DA; Verma S
    Am J Physiol Heart Circ Physiol; 2024 Aug; 327(2):H370-H376. PubMed ID: 38874618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014-2022).
    Lin J; Pearson SA; Greenfield JR; Park KH; Havard A; Brieger D; Day RO; Falster MO; de Oliveira Costa J
    Eur J Clin Pharmacol; 2023 Sep; 79(9):1239-1248. PubMed ID: 37449993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress.
    Luna-Marco C; Iannantuoni F; Hermo-Argibay A; Devos D; Salazar JD; Víctor VM; Rovira-Llopis S
    Free Radic Biol Med; 2024 Mar; 213():19-35. PubMed ID: 38220031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparative effects of metabolic surgery, SGLT2i, or GLP-1RA in patients with obesity and type 2 diabetes: a retrospective cohort study.
    Wu T; Wong CKH; Tang EHM; Man KKC; Wong SKH; Au ICH; Tse ETY; Chan EWY; Grieve E; Wu O; Ng EKW; Wong ICK
    Surg Obes Relat Dis; 2022 Jun; 18(6):762-771. PubMed ID: 35300912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection.
    Bertoccini L; Baroni MG
    Adv Exp Med Biol; 2021; 1307():193-212. PubMed ID: 32034729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential unrealized mortality benefit of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transport-2 inhibitors: A report from the Veterans Health Administration Clinical Assessment, Reporting and Tracking program.
    Salahuddin T; Richardson V; McNeal DM; Henderson K; Hess PL; Raghavan S; Saxon DR; Valle JA; Waldo SW; Ho PM; Schwartz GG
    Diabetes Obes Metab; 2021 Jan; 23(1):97-105. PubMed ID: 32902128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease.
    Hofer F; Kazem N; Schweitzer R; Hammer A; Jakse F; Koller L; Hengstenberg C; Sulzgruber P; Niessner A
    Cardiovasc Drugs Ther; 2021 Dec; 35(6):1161-1170. PubMed ID: 33666822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus.
    Sharma A; Verma S
    Can J Diabetes; 2020 Feb; 44(1):93-102. PubMed ID: 31882322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study.
    DeRemer CE; Vouri SM; Guo J; Donahoo WT; Winterstein AG; Shao H
    J Diabetes Complications; 2021 Sep; 35(9):107972. PubMed ID: 34247911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
    Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
    J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obesity management for the treatment of type 2 diabetes: emerging evidence and therapeutic approaches.
    Morissette A; Mulvihill EE
    J Pharm Pharm Sci; 2024; 27():13065. PubMed ID: 38903652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A New Age for Secondary Prevention: Optimal Medical Therapy for Stable Ischemic Heart Disease Among Patients with Diabetes and/or Obesity.
    Osude N; Pagidipati NJ
    Med Clin North Am; 2024 May; 108(3):469-487. PubMed ID: 38548458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019.
    McCoy RG; Van Houten HK; Deng Y; Mandic PK; Ross JS; Montori VM; Shah ND
    JAMA Netw Open; 2021 Feb; 4(2):e2035792. PubMed ID: 33523188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns.
    Lim S; Kim KM; Nauck MA
    Trends Endocrinol Metab; 2018 Apr; 29(4):238-248. PubMed ID: 29463450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes.
    Busch RS; Kane MP
    Postgrad Med; 2017 Sep; 129(7):686-697. PubMed ID: 28657399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration.
    Chang LS; Vaduganathan M; Plutzky J; Aroda VR
    Curr Diab Rep; 2019 Dec; 19(12):157. PubMed ID: 31802265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The elephant in the room: Why cardiologists should stop ignoring type 2 diabetes.
    O'Keefe JH; Nassif ME; Magwire ML; O'Keefe EL; Lavie CJ
    Prog Cardiovasc Dis; 2019; 62(4):364-369. PubMed ID: 31408637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.